{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:45:35Z","timestamp":1791888335503,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005616","name":"Allergan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.lungcan.2019.12.005","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T08:45:03Z","timestamp":1576485903000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-7464","authenticated-orcid":false,"given":"Jacob M.","family":"Sands","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Shivdasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian G.","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4040-1864","authenticated-orcid":false,"given":"Ryan S.","family":"Alden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi A.","family":"J\u00e4nne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank C.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey R.","family":"Oxnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette M.","family":"Sholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2019.12.005_bib0005","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2159-8290.CD-14-1129","article-title":"Next-generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov."},{"issue":"7417","key":"10.1016\/j.lungcan.2019.12.005_bib0010","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"C.G.A.R. Network","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.lungcan.2019.12.005_bib0015","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-11-2109","article-title":"Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR\/KRAS and presence of PIK3CA\/AKT1 mutations","volume":"18","author":"Rekhtman","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2019.12.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020351","article-title":"Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer","volume":"6","author":"Dutt","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.lungcan.2019.12.005_bib0025","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/2159-8274.CD-11-0005","article-title":"Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer","volume":"1","author":"Hammerman","year":"2011","journal-title":"Cancer Discov."},{"issue":"16","key":"10.1016\/j.lungcan.2019.12.005_bib0030","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-12-3950","article-title":"Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma","volume":"73","author":"Liao","year":"2013","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.lungcan.2019.12.005_bib0035","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-14-0284","article-title":"FGFR1\/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer","volume":"20","author":"Wang","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2019.12.005_bib0040","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2019.12.005_bib0045","doi-asserted-by":"crossref","DOI":"10.1097\/JTO.0000000000000607","article-title":"Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung Cancer (NSCLC): results from the phase II BASALT-1 study","author":"Vansteenkiste","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2019.12.005_bib0050","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/cam4.238","article-title":"Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors","volume":"3","author":"Salgia","year":"2014","journal-title":"Cancer Med."},{"issue":"10","key":"10.1016\/j.lungcan.2019.12.005_bib0055","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1158\/1078-0432.CCR-14-3039","article-title":"Squamous cell lung cancer: from tumor genomics to cancer therapeutics","volume":"21","author":"Gandara","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2019.12.005_bib0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.12.005_bib0065","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors","author":"Bahleda","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2019.12.005_bib0070","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/PAS.0000000000000439","article-title":"Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis","volume":"39","author":"Kadota","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.lungcan.2019.12.005_bib0075","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/JTO.0b013e31824c9485","article-title":"ALK-rearranged lung Cancer: adenosquamous lung Cancer Masquerading as pure squamous carcinoma","volume":"7","author":"Chaft","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2019.12.005_bib0080","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2019.12.005_bib0085","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/2159-8290.CD-11-0184","article-title":"High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing","volume":"2","author":"Wagle","year":"2012","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.lungcan.2019.12.005_bib0090","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in Cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"19","key":"10.1016\/j.lungcan.2019.12.005_bib0095","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87062","article-title":"Institutional implementation of clinical tumor profiling on an unselected cancer population","volume":"1","author":"Sholl","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.lungcan.2019.12.005_bib0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41379-019-0202-3","article-title":"Characteristics of mismatch repair deficiency in sarcomas","author":"Doyle","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2019.12.005_bib0105","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2019.12.005_bib0110","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lungcan.2019.12.005_bib0115","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","article-title":"BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers","volume":"8","author":"Maxwell","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.lungcan.2019.12.005_bib0120","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41467-017-00921-w","article-title":"Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes","volume":"8","author":"Riaz","year":"2017","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.lungcan.2019.12.005_bib0125","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1158\/0008-5472.CAN-18-1814","article-title":"Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.lungcan.2019.12.005_bib0130","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.lungcan.2019.12.005_bib0135","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jtho.2017.02.001","article-title":"Characteristics and outcomes of patients with lung Cancer Harboring multiple molecular alterations: results from the IFCT study biomarkers France","volume":"12","author":"Guibert","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2019.12.005_bib0140","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9054","article-title":"A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B","volume":"35","author":"Wade","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2019.12.005_bib0145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9056","article-title":"A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C","volume":"35","author":"Edelman","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2019.12.005_bib0150","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9055","article-title":"Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D","volume":"35","author":"Aggarwal","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2019.12.005_bib0155","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/his.13482","article-title":"Malignant mesothelioma with squamous differentiation","volume":"72","author":"Tanaka","year":"2018","journal-title":"Histopathology"},{"issue":"21","key":"10.1016\/j.lungcan.2019.12.005_bib0160","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.16276","article-title":"Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer","volume":"8","author":"Lindquist","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.lungcan.2019.12.005_bib0165","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cllc.2018.08.020","article-title":"Targeted tissue and cell-free tumor DNA sequencing of advanced lung squamous-cell carcinoma reveals clinically significant prevalence of actionable alterations","volume":"20","author":"Lam","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2019.12.005_bib0170","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jamaoncol.2018.0775","article-title":"Association of ERBB mutations with clinical outcomes of afatinib- or erlotinib-treated patients with lung squamous cell carcinoma: secondary analysis of the LUX-Lung 8 randomized clinical trial","volume":"4","author":"Goss","year":"2018","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2019.12.005_bib0175","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219307585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219307585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:33:50Z","timestamp":1759235630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219307585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":35,"alternative-id":["S0169500219307585"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}